PT  - JOURNAL ARTICLE
AU  - Portaccio, Emilio
AU  - Annovazzi, Pietro
AU  - Ghezzi, Angelo
AU  - Zaffaroni, Mauro
AU  - Moiola, Lucia
AU  - Martinelli, Vittorio
AU  - Lanzillo, Roberta
AU  - Brescia Morra, Vincenzo
AU  - Rinaldi, Francesca
AU  - Gallo, Paolo
AU  - Tortorella, Carla
AU  - Paolicelli, Damiano
AU  - Pozzilli, Carlo
AU  - De Giglio, Laura
AU  - Cavalla, Paola
AU  - Cocco, Eleonora
AU  - Marrosu, Maria Giovanna
AU  - Patti, Francesco
AU  - Solaro, Claudio
AU  - Bellantonio, Paolo
AU  - Uccelli, Antonio
AU  - Laroni, Alice
AU  - Pastò, Luisa
AU  - Giannini, Marta
AU  - Trojano, Maria
AU  - Comi, Giancarlo
AU  - Amato, Maria Pia
AU  - ,
TI  - Pregnancy decision-making in women with multiple sclerosis treated with natalizumab
AID  - 10.1212/WNL.0000000000005067
DP  - 2018 Mar 06
TA  - Neurology
PG  - e823--e831
VI  - 90
IP  - 10
4099  - http://n.neurology.org/content/90/10/e823.short
4100  - http://n.neurology.org/content/90/10/e823.full
SO  - Neurology2018 Mar 06; 90
AB  - Objective To assess fetal risk after pregnancy exposure to natalizumab in women with multiple sclerosis (MS), with a specific focus on spontaneous abortion (SA) and congenital anomalies (CA).Methods Data of all pregnancies occurring between 2009 and 2015 in patients with MS treated with natalizumab and referring to 19 participating sites were collected and compared with those of pregnancies in untreated patients and patients treated with injectable immunomodulatory agents. Rates of SA and CA were also compared with those reported in the Italian population. Multivariable logistic and linear regression models were performed.Results A total of 92 pregnancies were tracked in 83 women. In the multivariable analysis, natalizumab exposure was associated with SA (odds ratio [OR] 3.9, 95% confidence interval [CI] 1.9–8.5, p < 0.001). However, the rate of SA (17.4%) was within the estimates for the general population, as well as the rate of major CA (3.7%). Moreover, exposure to natalizumab and interferon-β (IFN-β) was associated with lower length and weight of the babies (p < 0.001).Conclusion Our results showed that natalizumab exposure to up 12 weeks of gestation is associated with an increased risk of SA, although within the limits expected in the general population, whereas the risk of CA needs further investigation. Taking into account the high risk of disease reactivation after natalizumab suspension, pregnancy could be planned continuing natalizumab while strictly monitoring conception.Classification of evidence This study provides Class III evidence that in women with MS, natalizumab exposure increases the risk of spontaneous abortion as compared to IFN-β-exposed or untreated patients (OR 3.9, 95% CI 1.9–8.5).CI=confidence interval; CP=control pregnancies; DMD=disease-modifying drug; EDSS=Expanded Disability Status Scale; EUROCAT=European Surveillance of Congenital Anomalies; IFN-β=interferon-β; IFNBEP=interferon-β-exposed pregnancies; MS=multiple sclerosis; NatEP=natalizumab-exposed pregnancies; OR=odds ratio; SA=spontaneous abortion